L-656, 575 (OCP-9-176): A NOVEL OXACEPHEM <i>IN VITRO</i> ACTIVITY AGAINST AEROBIC AND ANAEROBIC CLINICAL BACTERIAL ISOLATES

BARBARA WEISSBERGER; GEORGE K. ABRUZZO; ROBERT A. FROMTLING; MARY E. VALIANT; DANIEL L. SHUNGU; HANS H. GADEBUSCH

doi:10.7164/antibiotics.41.1130

L-656, 575 (OCP-9-176): A NOVEL OXACEPHEM

IN VITRO ACTIVITY AGAINST AEROBIC AND ANAEROBIC CLINICAL BACTERIAL ISOLATES

BARBARA WEISSBERGER, GEORGE K. ABRUZZO, ROBERT A. FROMTLING, MARY E. VALIANT, DANIEL L. SHUNGU, HANS H. GADEBUSCH

Author information

JOURNAL FREE ACCESS

1988 Volume 41 Issue 8 Pages 1130-1136

DOI https://doi.org/10.7164/antibiotics.41.1130

Details

Abstract

L-656, 575 (OCP-9-176) is a novel oxacephem superior to ceftazidime in in vitro activity against clinical isolates of Enterobacter species, methicillin-susceptibleStaphylococcus aureus and Staphylococcus epidermidis, and multiply-resistant Pseudomonas aeruginosa. Our results suggest that L-656, 575 has a high affinity for penicillin binding proteins of Pseudomonas and may bind preferentially to PBP-3 in this organism. L-656, 575 is active against β-Mactamase derepressed Enterobacteriaceae and ceftazidime-resistant P. aeruginosa.

Corresponding author

Register with J-STAGE for free!